The Journal of Medical Investigation
Online ISSN : 1349-6867
Print ISSN : 1343-1420
ISSN-L : 1343-1420
Clinical Characteristics and Macrolide Resistance of Mycoplasma pneumoniae in Taiwanese Children:A Post-Pandemic Analysis (2024–2025)
Chun Liu, Shun-Cheng Yang, Chao-Jen Lin, Kan-Hsuan Lin, Cheng-Han Lee, Chih-Chi Huang, Jun-Kai Kao
Author information
JOURNAL FREE ACCESS

2026 Volume 73 Issue 3.4 Pages 344-350

Details
Abstract

The resurgence of Mycoplasma pneumoniae infections following the coronavirus disease 2019 pandemic has elicited significant concerns regarding alterations in epidemiology, clinical presentation, and antimicrobial resistance patterns. This study examined the clinical characteristics, co-infection profiles, and antimicrobial resistance patterns of M. pneumoniae in hospitalized Taiwanese children during the 2024–2025 surge period. This retrospective cohort study included 93 pediatric inpatients. Diagnosis was established through an integrated assessment of serum immunoglobulin M, polymerase chain reaction, and chest radiography findings, verified by two pediatric infectious disease specialists. Resistance was categorized based on clinical treatment failure (Macrolide and Clinical-resistance) or proactive use of second-line agents (Probable-resistance). Among the 79 confirmed M. pneumoniae cases, 55.7% were mono-infections, with Haemophilus influenzae identified as the most frequent bacterial co-pathogen. Macrolide, Clinical, and Probable-resistance rates were 19.0%, 31.6%, and 87.3%, respectively. A notable shift in empirical prescriptions was observed, with macrolide use declining from 38.24% to 13.73% during the study period. Radiographic severity was significantly associated with fever duration. Receiver operating characteristic analysis indicated that conventional biomarkers exhibited poor predictive power for resistance. In conclusion, clinical management should prioritize early assessment of treatment responses and clinical progress over specific biomarker thresholds in this complex post-pandemic immunological landscape. J. Med. Invest. 73 : 344-350, August, 2026

Content from these authors
© by The University of Tokushima Faculty of Medicine
Previous article Next article
feedback
Top